Amedeo Smart

Free Medical Literature Service

 

Amedeo

Schizophrenia
  Free Subscription

Articles published in
J Clin Psychopharmacol
    April 2024
  1. SCALA M, Martinez Trapote P, Rodriguez-Jimenez R, Pecorino B, et al
    Managing a Treatment-Resistant Schizophrenia Spectrum Disorder With a Hormonal Twist in a Female Patient: A Case Report of a Progestin-Only Pill.
    J Clin Psychopharmacol. 2024 Apr 9. doi: 10.1097/JCP.0000000000001836.
    >> Share

    March 2024
  2. KORKMAZ SA, Koca E, Yilmaz O, Ozbek T, et al
    Real-World Evidence of Antipsychotic Monotherapy Versus Polypharmacy in the Treatment of Schizophrenia Spectrum Disorders.
    J Clin Psychopharmacol. 2024 Mar 5. doi: 10.1097/JCP.0000000000001837.
    >> Share

  3. NAGANO M, Susuta Y, Masui H, Watanabe Y, et al
    Efficacy and Safety of Valbenazine in Japanese Patients With Tardive Dyskinesia and Schizophrenia/Schizoaffective Disorder or Bipolar Disorder/Depressive Disorder: Primary Results and Post Hoc Analyses of the J-KINECT Study.
    J Clin Psychopharmacol. 2024;44:107-116.
    >> Share

    February 2024
  4. MORI Y, Watanabe K, Suzuki Y, Ono H, et al
    Clozapine-Associated Myocarditis in a Patient With Schizophrenia Taking Lemborexant: A Case Report.
    J Clin Psychopharmacol. 2024 Feb 8. doi: 10.1097/JCP.0000000000001817.
    >> Share

  5. DIMA A, Abdelsamie A, Clark-Castillo R, Webb-Wilson H, et al
    Overcoming Obstacles to Clozapine Treatment: A Case of Clozapine Rechallenge in ECT-Resistant Schizophrenia With Catatonic Features.
    J Clin Psychopharmacol. 2024 Feb 5. doi: 10.1097/JCP.0000000000001819.
    >> Share

    January 2024
  6. WATANABE M, Misawa F, Takeuchi H
    Real-World Effectiveness of High-Dose Olanzapine and Clozapine for Treatment-Resistant Schizophrenia in Japan: A Retrospective Bidirectional Mirror-Image Study.
    J Clin Psychopharmacol. 2024 Jan 26. doi: 10.1097/JCP.0000000000001804.
    >> Share

  7. KJELBY E, Gjestad R, Fathian F, Sinkeviciute I, et al
    Reply to a Letter to the Editors From Dr de Souza and colleagues: "Unraveling the Optimal Treatment Approach for Depression in Schizophrenia Spectrum: A Quest for Clarity".
    J Clin Psychopharmacol. 2024;44:76-78.
    >> Share

  8. DE SOUZA JUNIOR SA, Cavalcante da Rocha ME, Marques Andrade AG, Fernandes de Moraes CL, et al
    Unraveling the Optimal Treatment Approach for Depression in Schizophrenia Spectrum: A Quest for Clarity.
    J Clin Psychopharmacol. 2024;44:74-76.
    >> Share

  9. MOHAMMAD-GHOLIZAD F, Karimzadeh I, Moghimi-Sarani E, Arshadi M, et al
    Evaluation and Comparison of the Effectiveness of Atropine Eye Drops, Ipratropium Bromide Nasal Spray, and Amitriptyline Tablet in the Management of Clozapine-Associated Sialorrhea in Patients With Refractory Schizophrenia: A Randomized Clinical Trial
    J Clin Psychopharmacol. 2024;44:9-15.
    >> Share

  10. KARACAM DOGAN M, Yildiz FG, Temucin CM, Ertugrul A, et al
    Effects of Clozapine on Cortical Inhibition: A Transcranial Magnetic Stimulation Follow-up Study.
    J Clin Psychopharmacol. 2024;44:16-24.
    >> Share

    November 2023
  11. LEE MA, Cola P, Jayathilake K, Meltzer HY, et al
    Reply to Dr Yucel's Comments on the Article "Long-term Outcome of Clozapine in Treatment-Resistant Schizophrenia".
    J Clin Psychopharmacol. 2023;43:555-556.
    >> Share

  12. YUCEL A
    Critical Feedback on Article by Lee and Colleagues: "Long-Term Outcome of Clozapine in Treatment-Resistant Schizophrenia".
    J Clin Psychopharmacol. 2023;43:555.
    >> Share

  13. KINDT H, Mahgoub Y
    Should We Be Prescribing Stimulants to Patients With Multiple Sclerosis?: A Case Report of Stimulant-Associated Psychosis.
    J Clin Psychopharmacol. 2023;43:551-553.
    >> Share

  14. MAGISTRI C, Mellini C
    Clozapine-Associated Agranulocytosis: A Systematic Review. Is It Really So Frighteningly Common?
    J Clin Psychopharmacol. 2023;43:527-533.
    >> Share

  15. CONATY O, Doherty AM, Lally J
    Severe Alprazolam Withdrawal With Delirium and Psychosis: A Case Report and Literature Review.
    J Clin Psychopharmacol. 2023;43:511-513.
    >> Share

    September 2023
  16. KINDT H, Mahgoub Y
    Should We Be Prescribing Stimulants to Patients With Multiple Sclerosis? A Case Report of Stimulant-Associated Psychosis.
    J Clin Psychopharmacol. 2023 Sep 29. doi: 10.1097/JCP.0000000000001766.
    >> Share

  17. CONATY O, Doherty AM, Lally J
    Severe Alprazolam Withdrawal With Delirium and Psychosis. A Case Report and Literature Review.
    J Clin Psychopharmacol. 2023 Sep 7. doi: 10.1097/JCP.0000000000001758.
    >> Share

  18. TKACH N, Opler DJ
    A Consideration for the Study of the Use of Cyproheptadine in Parkinson Disease Psychosis.
    J Clin Psychopharmacol. 2023;43:481-482.
    >> Share

  19. DE LIMA DN JR, Frota IJ, Macedo DS, Sanders LLO, et al
    Alpha Lipoic Acid for Schizophrenia: Future Investigations With Low Doses and Treatment-Resistant Patients-Reply to Letter by Kishi and Colleagues.
    J Clin Psychopharmacol. 2023;43:478-479.
    >> Share

  20. KISHI T, Sakuma K, Miura G, Ito Y, et al
    Alpha Lipoic Acid for Schizophrenia: A Systematic Review and Meta-analysis.
    J Clin Psychopharmacol. 2023;43:477-478.
    >> Share

  21. BROTHWOOD PL, Husain M, Pinson J, Oloyede E, et al
    Clozapine in Combination With Olanzapine Long-Acting Injection: The Intersection of Treatment-Resistant Schizophrenia and Poor Medication Adherence-A Case Report.
    J Clin Psychopharmacol. 2023;43:472-474.
    >> Share

  22. JOGI L, Subu O, Jaishankar P, Kumar V, et al
    Management of Treatment-Resistant Schizophrenia in a Patient With Epilepsy With Add on Low-Dose Clozapine-A Case Report.
    J Clin Psychopharmacol. 2023;43:468-469.
    >> Share

    August 2023
  23. JOGI L, Subu O, Jaishankar P, Kumar V, et al
    Management of Treatment-Resistant Schizophrenia in a Patient With Epilepsy With Add on Low-Dose Clozapine-A Case Report.
    J Clin Psychopharmacol. 2023 Aug 8. doi: 10.1097/JCP.0000000000001737.
    >> Share

  24. BROTHWOOD PL, Husain M, Pinson J, Oloyede E, et al
    Clozapine in Combination With Olanzapine Long-Acting Injection: The Intersection of Treatment-Resistant Schizophrenia and Poor Medication Adherence-A Case Report.
    J Clin Psychopharmacol. 2023 Aug 8. doi: 10.1097/JCP.0000000000001746.
    >> Share

  25. TKACH N, Opler DJ
    Letter to the Editors: A Consideration for the Study of the Use of Cyproheptadine in Parkinson Disease Psychosis.
    J Clin Psychopharmacol. 2023 Aug 7. doi: 10.1097/JCP.0000000000001743.
    >> Share

    July 2023
  26. RODIN I, Evans A
    Case of Clozapine-Associated Negative Myoclonus.
    J Clin Psychopharmacol. 2023;43:386-387.
    >> Share

    May 2023
  27. ONITSUKA T, Okada T, Hasegawa N, Tsuboi T, et al
    Combination Psychotropic Use for Schizophrenia With Long-Acting Injectable Antipsychotics and Oral Antipsychotics: A Nationwide Real-World Study in Japan.
    J Clin Psychopharmacol. 2023 May 23. doi: 10.1097/JCP.0000000000001704.
    >> Share


  28. Clozapine blood concentration predicts corrected QT-interval prolongation in patients with psychoses: Erratum.
    J Clin Psychopharmacol. 2023;43:304.
    >> Share

  29. STREIFF RA
    Institutional Neglect of Anosognosia Is a Critical Barrier in the Treatment of Psychosis Related Disorders.
    J Clin Psychopharmacol. 2023;43:200-203.
    >> Share

    April 2023
  30. KJELBY E, Gjestad R, Fathian F, Sinkeviciute I, et al
    Antidepressive Effectiveness of Amisulpride, Aripiprazole, and Olanzapine in Patients With Schizophrenia Spectrum Disorders: A Secondary Outcome Analysis of a Pragmatic, Randomized Trial (BeSt InTro).
    J Clin Psychopharmacol. 2023 Apr 22. doi: 10.1097/JCP.0000000000001679.
    >> Share

  31. MALHAM KM, Miller BJ
    Long-Acting Injectable Antipsychotics and Infections in Schizophrenia.
    J Clin Psychopharmacol. 2023 Apr 18. doi: 10.1097/JCP.0000000000001694.
    >> Share

    March 2023
  32. LEE MA, Cola P, Jayathilake K, Meltzer HY, et al
    Long-Term Outcome of Clozapine in Treatment-Resistant Schizophrenia.
    J Clin Psychopharmacol. 2023 Mar 29. doi: 10.1097/JCP.0000000000001671.
    >> Share

  33. MALALI METIN H, Aksu T, Akyildiz UO, Sevincok L, et al
    Cerebellar Cognitive Affective Syndrome and Delusional Disorder Associated With Long-Term Phenytoin Use: A Case Report.
    J Clin Psychopharmacol. 2023;43:184-186.
    >> Share

    February 2023
  34. OLIVOLA M, Arienti V, Bassetti N, Giovanna G, et al
    Lurasidone Augmentation of Clozapine in Refractory Schizophrenia: A Case Series.
    J Clin Psychopharmacol. 2023 Feb 27. doi: 10.1097/JCP.0000000000001662.
    >> Share

  35. BOGERS JPAM, Schulte PFJ, Broekman TG, de Haan L, et al
    Feasibility and Effect of Increasing Clozapine Plasma Levels in Long-Stay Patients With Treatment-Resistant Schizophrenia.
    J Clin Psychopharmacol. 2023 Feb 27. doi: 10.1097/JCP.0000000000001657.
    >> Share

  36. LAGREULA J, Ferraiolo M, De Timary P, Delatte B, et al
    Impact of a Caffeine Restriction Policy on Inpatients With Schizophrenia: A Pre-Post Comparison Using Electronic Health Records.
    J Clin Psychopharmacol. 2023 Feb 27. doi: 10.1097/JCP.0000000000001670.
    >> Share

  37. ARMSTRONG AG, Preskorn SH
    Thoughts on the Value of Case Series in the Literature: An Example Using the Article on Lurasidone Augmentation of Clozapine in Refractory Schizophrenia.
    J Clin Psychopharmacol. 2023 Feb 24. doi: 10.1097/JCP.0000000000001676.
    >> Share

  38. TIRUPATI S
    Ultra-Treatment-Resistant Schizophrenia and Clozapine Augmentation.
    J Clin Psychopharmacol. 2023 Feb 1. doi: 10.1097/JCP.0000000000001652.
    >> Share

    January 2023
  39. SHUKLA A, Nandan NK, Singh LK
    Acute Psychosis After Immunization With Whole-Virion Inactivated COVID-19 Vaccine; A Case Report From Central India.
    J Clin Psychopharmacol. 2023;43:66-67.
    >> Share

  40. DE LIMA DN JR, Costa Filho CWL, Frota IJ, de Oliveira ALB, et al
    alpha-Lipoic Acid as Adjunctive Treatment for Schizophrenia: A Randomized Double-Blind Study.
    J Clin Psychopharmacol. 2023;43:39-45.
    >> Share

  41. CUOMO A, Aguglia E, Biagini S, Carano A, et al
    Two-Injection Start Regimen of Long-Acting Aripiprazole in 133 Patients With Schizophrenia.
    J Clin Psychopharmacol. 2023;43:35-38.
    >> Share

    November 2022
  42. KIM K, Kim YS, Joo EJ, Kim EJ, et al
    Clozapine Blood Concentration Predicts Corrected QT-Interval Prolongation in Patients With Psychoses.
    J Clin Psychopharmacol. 2022;42:536-543.
    >> Share

  43. CONTRUCCI RR, Heikens M, Beex-Oosterhuis MM
    Case Report: Blepharospasms After the Use of Long-Acting Paliperidone Injections.
    J Clin Psychopharmacol. 2022;42:608-609.
    >> Share

    October 2022
  44. DING J, Zhang Y, Zhang Y, Yang L, et al
    Effects of Age, Sex, and Comedication on the Plasma Concentrations of Olanzapine in Chinese Patients With Schizophrenia Based on Therapeutic Drug Monitoring Data.
    J Clin Psychopharmacol. 2022 Oct 25. pii: 00004714-990000000-00067.
    >> Share

  45. JU V, Walkerly A, VandenBerg A, Shobassy A, et al
    New Onset of Seizures and Psychosis in a Patient Who Is Coprescribed Atomoxetine and Bupropion: A Case Report.
    J Clin Psychopharmacol. 2022 Oct 4. pii: 00004714-990000000-00056.
    >> Share

  46. OKADA T, Hori H, Hasegawa N, Murata A, et al
    Second-Generation Antipsychotic Monotherapy Contributes to the Discontinuation of Anticholinergic Drugs in Hospitalized Patients With Schizophrenia.
    J Clin Psychopharmacol. 2022 Oct 4. pii: 00004714-990000000-00057.
    >> Share

  47. DARWISH M, Bugarski-Kirola D, Passarell J, Owen J, et al
    Pimavanserin Exposure-Response Analyses in Patients With Schizophrenia: Results From the Phase 2 ADVANCE Study.
    J Clin Psychopharmacol. 2022 Oct 3. pii: 00004714-990000000-00053.
    >> Share

    September 2022
  48. TEODORO T, Nogueira V, Aldeias J, Teles Martins M, et al
    Clozapine Associated Periorbital Edema in First Episode Psychosis: A Case Report of a Rare Adverse Effect in Treatment-Resistant Schizophrenia.
    J Clin Psychopharmacol. 2022 Sep 5. pii: 00004714-990000000-00049.
    >> Share

  49. HORIKOSHI S, Miura I, Mui A, Hikichi T, et al
    Second-Generation Antipsychotic Long-Acting Injection Reduced the Time of Restrictive Interventions in Patients With Schizophrenia: Retrospective, A 4-Year Mirror-Image Study.
    J Clin Psychopharmacol. 2022 Sep 5. pii: 00004714-990000000-00048.
    >> Share

  50. KANE JM
    A New Treatment Paradigm: Targeting Trace Amine-Associated Receptor 1 (TAAR1) in Schizophrenia.
    J Clin Psychopharmacol. 2022;42.
    >> Share

  51. SATODIYA RM, Brown VR, Njuguna SW, Bied AM, et al
    A Systematic Review of Clinical Trials on Lumateperone and Its Effects on Body Weight.
    J Clin Psychopharmacol. 2022;42:495-499.
    >> Share

    August 2022
  52. ZHAND N, Labelle A, Ghanem D, Gujral P, et al
    Comparison of Extrapyramidal Symptoms Among Outpatients With Schizophrenia on Long-Acting Injectable Antipsychotics.
    J Clin Psychopharmacol. 2022 Aug 17. pii: 00004714-990000000-00044.
    >> Share

    July 2022
  53. TIEN Y, Huang SC
    Aripiprazole-Associated Acute Dystonia During Dose Reduction in Patient With Schizophrenia and Dementia: A Case Report.
    J Clin Psychopharmacol. 2022 Jul 2. pii: 00004714-990000000-00031.
    >> Share

  54. GROVER S, Naskar C, Chakrabarti S
    Factors Associated With Poor Response to Clozapine in Schizophrenia: A Study From Northern India.
    J Clin Psychopharmacol. 2022;42:345-349.
    >> Share

  55. GONZALEZ-RODRIGUEZ A, Monreal JA
    Time for Rational Pharmacotherapy in Delusional Disorder: New Targets for Old Clinical Observations.
    J Clin Psychopharmacol. 2022;42:413-414.
    >> Share

  56. BECHARD L, Morasse-Begis M, Corbeil O, Hakim JR, et al
    Clozapine Rechallenge or Continuation Despite Neutropenia, an Extended Follow-up of a Consecutive Quebec Case Series.
    J Clin Psychopharmacol. 2022;42:391-395.
    >> Share

    June 2022
  57. KOGURE M, Kanahara N, Kimura M, Hanaoka S, et al
    Long-Term Treatment With Long-Acting Injectable Antipsychotic in Schizophrenia Patients With and Without Dopamine Supersensitivity Psychosis: A 6-Year Retrospective Comparative Study.
    J Clin Psychopharmacol. 2022 Jun 17. pii: 00004714-990000000-00026.
    >> Share

  58. CHIU CC, Lin C, Chen WY, Chen CR, et al
    Therapeutic Drug Monitoring of Paliperidone in Patients With Schizophrenia in Taiwan.
    J Clin Psychopharmacol. 2022 Jun 14. pii: 00004714-990000000-00023.
    >> Share

  59. WANG D, Wei N, Hu F, Li J, et al
    Paliperidone Extended Release Versus Olanzapine in Treatment-Resistant Schizophrenia: A Randomized, Double-Blind, Multicenter Study.
    J Clin Psychopharmacol. 2022 Jun 10. pii: 00004714-990000000-00019.
    >> Share

    May 2022
  60. GALLAGHER KE, Funaro MC, Woods SW
    Prescription Stimulants and the Risk of Psychosis: A Systematic Review of Observational Studies.
    J Clin Psychopharmacol. 2022;42:308-314.
    >> Share

    March 2022
  61. YEE CS, Bahji A, Lolich M, Vazquez GH, et al
    Comparative Efficacy and Tolerability of Antipsychotics for Juvenile Psychotic Disorders: A Systematic Review and Network Meta-Analysis.
    J Clin Psychopharmacol. 2022;42:198-208.
    >> Share

  62. FRANKENBURG FR, Malvesti S
    Paliperidone and Edema.
    J Clin Psychopharmacol. 2022;42:225-226.
    >> Share

    February 2022
  63. TAKAKI M, Yada Y, Sakamoto S, Fujiwara M, et al
    A Decrease of Neutrophils After COVID-19 Vaccination in a Treatment-Resistant Patient With Schizophrenia Taking Clozapine.
    J Clin Psychopharmacol. 2022 Feb 10. pii: 00004714-900000000-98207.
    >> Share

    January 2022
  64. WANG XY, Chan HY, Lin CH
    Time to Rehospitalization for Different Oral Risperidone Dosing Frequencies in Patients With Schizophrenia: A 17-Year Retrospective Cohort Study.
    J Clin Psychopharmacol. 2022 Jan 6. pii: 00004714-900000000-98219.
    >> Share

  65. CINTRON PASTRANA MA, Quintana Aviles E
    Treatment of Refractory Schizophrenia With Clozapine in a Patient With Wolff-Parkinson-White Syndrome.
    J Clin Psychopharmacol. 2022;42:95-96.
    >> Share

  66. HE L, Yu Y, Zhang L, He S, et al
    A Real-World Study of Risk Factors for QTc Prolongation in Schizophrenia Patients Receiving Atypical Antipsychotics.
    J Clin Psychopharmacol. 2022;42:71-74.
    >> Share

  67. SMITH RL, Wollmann BM, Kylleso L, Tran TTA, et al
    Effect of Valproic Acid on the Metabolic Spectrum of Clozapine in Patients With Schizophrenia.
    J Clin Psychopharmacol. 2022;42:43-50.
    >> Share

  68. STROMME MF, Mellesdal LS, Bartz-Johannesen CA, Kroken RA, et al
    Use of Benzodiazepines and Antipsychotic Drugs Are Inversely Associated With Acute Readmission Risk in Schizophrenia.
    J Clin Psychopharmacol. 2022;42:37-42.
    >> Share

  69. GARRIGA M, Mallorqui A, Bernad S, Ruiz-Cortes V, et al
    Antipsychotic-Associated Weight Gain and Clinical Improvement Under Clozapine Treatment.
    J Clin Psychopharmacol. 2022;42:75-80.
    >> Share

  70. BONNET U, Knierim U, Ronge R, Jahn J, et al
    Late-Onset Polyserositis Emerging During Long-Term Clozapine Treatment and Persisting After Clozapine Discontinuation: Is Clozapine Really Innocent?
    J Clin Psychopharmacol. 2022;42:106-107.
    >> Share

  71. ERDOGAN A, Ilhan F
    Risperidone-Associated Acute Laryngeal Dystonia: A Case Report.
    J Clin Psychopharmacol. 2022;42:98-99.
    >> Share

    November 2021
  72. MAURI MC, Franco G, Minutillo A, Paletta S, et al
    The Switch From Paliperidone Long-Acting Injectable 1- to 3-Monthly: Clinical Pharmacokinetic Evaluation in Patients With Schizophrenia (Preliminary Data).
    J Clin Psychopharmacol. 2021 Nov 24. pii: 00004714-900000000-98229.
    >> Share

  73. RUDA D, Jensen KG, Decara MS, Klauber DG, et al
    CYP2D6 Genotyping and Antipsychotic-Associated Extrapyramidal Adverse Effects in a Randomized Trial of Aripiprazole Versus Quetiapine Extended Release in Children and Adolescents, Aged 12-17 Years, With First Episode Psychosis.
    J Clin Psychopharmacol. 2021;41:667-672.
    >> Share

  74. WEIZMAN S, Shelef A, Bloemhof Bris E, Stryjer R, et al
    A Double-Blind, Placebo-Controlled Trial of Bupropion Add-on to Olanzapine or Risperidone in Overweight Individuals With Schizophrenia.
    J Clin Psychopharmacol. 2021;41:629-631.
    >> Share

  75. COMAI S, Fuamba Y, Rivolta MC, Gobbi G, et al
    Lifetime Cannabis Use Disorder Is Not Associated With Lifetime Impulsive Behavior and Severe Violence in Patients With Schizophrenia Spectrum Disorders From a High-Security Hospital.
    J Clin Psychopharmacol. 2021;41:623-628.
    >> Share

  76. MAKHLOUF AT, Van Alphen MU, Manzano GS, Freudenreich O, et al
    A Seizure After COVID-19 Vaccination in a Patient on Clozapine.
    J Clin Psychopharmacol. 2021;41:689-690.
    >> Share

  77. CELLINI L, De Donatis D, Mercolini L, Panariello F, et al
    Switch to 3-Month Long-Acting Injectable Paliperidone May Decrease Plasma Levels: A Case Series.
    J Clin Psychopharmacol. 2021;41:694-696.
    >> Share

  78. OKEYA K, Misawa F, Fujii Y, Takeuchi H, et al
    Olanzapine Reduction From High Dose to Standard Dose: A Retrospective Chart Review.
    J Clin Psychopharmacol. 2021;41:676-680.
    >> Share

  79. SELCUK M
    Tardive Myoclonus Responsive to Clozapine Misdiagnosed as Restless Leg Syndrome: A Case Report.
    J Clin Psychopharmacol. 2021;41:692-694.
    >> Share

    September 2021
  80. SRIFUENGFUNG M, Sukakul T, Pummangura C, Srifuengfung S, et al
    Oral Ulcers as an Unpredictable Adverse Reaction to Quetiapine Use in a Patient With Schizophrenia.
    J Clin Psychopharmacol. 2021 Sep 9. pii: 00004714-900000000-98247.
    >> Share

  81. MASHIMA Y, Uchida H, Kinoshita S, Arita Y, et al
    Camptocormia Secondary to Antipsychotic-Associated Dystonia of the Rectus Abdominis Muscles Detected by Abdominal Computed Tomography: A Case Report.
    J Clin Psychopharmacol. 2021;41:608-610.
    >> Share

  82. CUOMO A, Chioccioli M, Cattaneo CI, Magnani PA, et al
    Effectiveness of Intramuscular Chlorpromazine for Rapid Treatment of Psychomotor Agitation: A Naturalistic, Retrospective, and Observational Study.
    J Clin Psychopharmacol. 2021;41:613-614.
    >> Share

    August 2021
  83. PEITL V, Badzim VA, Sisko Markos I, Rendulic A, et al
    Improvements of Frontotemporal Cerebral Blood Flow and Cognitive Functioning in Patients With First Episode of Schizophrenia Treated With Long-Acting Aripiprazole.
    J Clin Psychopharmacol. 2021 Aug 26. pii: 00004714-900000000-98248.
    >> Share

  84. OGAWA T, Tachikawa H, Shiratori Y, Sodeyama N, et al
    Use of Blonanserin Transdermal Patch in Home Treatment of Schizophrenia: A Case Study.
    J Clin Psychopharmacol. 2021 Aug 23. pii: 00004714-900000000-98251.
    >> Share

  85. LIM M, Li Z, Xie H, Tan BL, et al
    The Effect of Therapeutic Alliance on Attitudes Toward Psychiatric Medications in Schizophrenia.
    J Clin Psychopharmacol. 2021 Aug 13. pii: 00004714-900000000-98260.
    >> Share

    July 2021

  86. Association of Aripiprazole With Reduced Hippocampal Atrophy During Maintenance Treatment of First-Episode Schizophrenia: Erratum.
    J Clin Psychopharmacol. 2021;41:507.
    >> Share

  87. AFTAB R, Pereira M, Hewitt J, Whale R, et al
    Effectiveness and Predictors of Discontinuation of Aripiprazole Long-acting Injection: A 12-Month Naturalistic Cohort Study.
    J Clin Psychopharmacol. 2021;41:478-483.
    >> Share

  88. GLICK ID, Cerfolio NE, Kamis D, Laurence M, et al
    Domestic Mass Shooters: The Association With Unmedicated and Untreated Psychiatric Illness.
    J Clin Psychopharmacol. 2021;41:366-369.
    >> Share

  89. SINKEVICIUTE I, Hugdahl K, Bartz-Johannessen C, Kroken RA, et al
    Differential Effectiveness of Atypical Antipsychotics on Hallucinations: A Pragmatic Randomized Controlled Trial.
    J Clin Psychopharmacol. 2021;41:389-396.
    >> Share

  90. SUHAS S, Manchegowda S, Venkatasubramanian G, Kumar V, et al
    Clozapine and Oral Contraceptives-Implications Beyond Pharmacokinetics: A Case Report.
    J Clin Psychopharmacol. 2021;41:487-490.
    >> Share

    June 2021
  91. KOREKI A, Mori H, Nozaki S, Koizumi T, et al
    Risk of Nonalcoholic Fatty Liver Disease in Patients With Schizophrenia Treated With Antipsychotic Drugs: A Cross-sectional Study.
    J Clin Psychopharmacol. 2021 Jun 4. pii: 00004714-900000000-98299.
    >> Share

    May 2021
  92. SUHAS S, Shivani S, Singh GK, Venkatasubramanian G, et al
    Festina Lente: Betahistine for Clozapine-Associated Weight Gain: A Case Report.
    J Clin Psychopharmacol. 2021;41:332-333.
    >> Share

  93. SUZUKI K, Castelli M, Komaroff M, Starling B, et al
    Pharmacokinetic Profile of the Asenapine Transdermal System (HP-3070).
    J Clin Psychopharmacol. 2021;41:286-294.
    >> Share

  94. MATHUR R, Singh J, Sood M
    A Case Report of Clozapine-Associated Stuttering and Amisulpride-Associated Stuttering and Seizure in an Adult on Concurrent Fluoxetine Therapy.
    J Clin Psychopharmacol. 2021;41:330-332.
    >> Share

  95. TIRUPATI S, Gordon T
    Continuation of Treatment With Clozapine After an Episode of Neutropenia.
    J Clin Psychopharmacol. 2021;41:320-322.
    >> Share

    April 2021
  96. GUIMARAES TM, Guimaraes MRC, Oliveira IAF, Leoni RF, et al
    Mononitrate Isosorbide as an Adjunctive Therapy in Schizophrenia: A Randomized Controlled Crossover Trial.
    J Clin Psychopharmacol. 2021 Apr 14. pii: 00004714-900000000-98311.
    >> Share

  97. LINDENMAYER JP, Rizvi S
    Augmentation With Pimavanserin in Treatment Refractory Schizophrenia: Case Report.
    J Clin Psychopharmacol. 2021 Apr 13. pii: 00004714-900000000-98312.
    >> Share

    March 2021
  98. AN H, Fan H, Chen S, Qi S, et al
    Effects of Dose, Age, Sex, Body Weight, and Smoking on Plasma Concentrations of Olanzapine and N-desmethyl Olanzapine in Inpatients With Schizophrenia.
    J Clin Psychopharmacol. 2021 Mar 31. pii: 00004714-900000000-98320.
    >> Share

  99. WANG J, Hart KL, Qi W, Ardekani BA, et al
    Association of Aripiprazole With Reduced Hippocampal Atrophy During Maintenance Treatment of First-Episode Schizophrenia.
    J Clin Psychopharmacol. 2021 Mar 31. pii: 00004714-900000000-98319.
    >> Share

  100. REHIMINI S, Goddard KG, Margolese HC
    Exceptionally High Clozapine-Associated Eosinophilia.
    J Clin Psychopharmacol. 2021;41:216-218.
    >> Share

  101. GROVER S, Naskar C, Chakrabarti S
    Does the Starting of Clozapine Influence Coprescription of Other Medications?: A Study From India.
    J Clin Psychopharmacol. 2021;41:148-154.
    >> Share

  102. GRIFFIN JM, Woznica E, Gilotra NA, Nucifora FC Jr, et al
    Clozapine-Associated Myocarditis: A Protocol for Monitoring Upon Clozapine Initiation and Recommendations for How to Conduct a Clozapine Rechallenge.
    J Clin Psychopharmacol. 2021;41:180-185.
    >> Share

  103. YILDIZ MI, Karacam Dogan M, Mutlu E, Abdullayeva L, et al
    All in One: Clozapine-Associated Acute Pancreatitis With Multiple Organ Involvement.
    J Clin Psychopharmacol. 2021;41:214-216.
    >> Share

  104. KHURRAM SK, Ames M, Muniz J
    Case Report: Valbenazine as a Treatment for Tardive Dyskinesia and Unexpected Antipsychotic Effects.
    J Clin Psychopharmacol. 2021;41:220-221.
    >> Share

  105. MISAWA F, Fujii Y, Takeuchi H
    Can a 4-Month Tolerability Assessment With Paliperidone Palmitate 1-Monthly Prevent Neuroleptic Malignant Syndrome Associated With the 3-Monthly?: Analysis Based on a Spontaneous Reporting System Database in Japan.
    J Clin Psychopharmacol. 2021;41:206-207.
    >> Share

  106. DANILEWITZ M, Rafizadeh R, Bousman CA
    Successful Clozapine Rechallenge After Suspected Clozapine-Associated Myocarditis: A Case Report.
    J Clin Psychopharmacol. 2021;41:218-220.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016